Sellami-Mnif Houda 1 , Umehara Toshihiro 1 , Yamazaki Yuriko 1 , Otake Hiroyuki 1 , Matoba Reie 1 , Sakashita Anna 1 , Matsuda Masafumi 1 Show Affiliations »
Abstract
OBJECTIVES: The introduction of liraglutide in the treatment of patients with type 2 diabetes already taking insulin is still subject to discussion in terms of timing and benefits. Gradually intensive insulin therapy is hastily prescribed. Switching from multiple insulin injection (MII) to insulin and liraglutide is evaluated in this study. METHODOLOGY: We studied 92 patients with type 2 diabetes previously under MII, C-peptide ≥ 1.5 ng/ml, divided into a group with reasonable glycemic control [RC: HbA1c < 8% (64 mmol/mol)] and another with a poor control [PC: HbA1c ≥ 8%, (64 mmol/mol)] after introduction of liraglutide and insulin therapy. RESULTS: Except for HbA1c, there were no statistical differences between RC and PC groups. Basal insulin doses were adjusted to achieve the fasting plasma glucose of 90-120 mg/dl. HbA1c was significantly improved in both groups, from 9.6% ± 1.6 (81 mmol/mol) and 7.0% ± 0.6 (53 mmol/mol) to 8.0% ± 1.5 (64 mmol/mol) and 6.8 ± 0.5% (51 mmol/mol). Reduction of body weight was significant only in RC (from 70 ± 16 kg to 68 ± 16 kg, p < 0.01). All patients from RC group and 58% of PC group reached HbA1c < 8% without hypoglycemia. CONCLUSION: This observation persuades us to propose the liraglutide and insulin combination to patients with C-peptide ≥ 1.5 ng/ml, regardless of the HbA1c. © The Japan Diabetes Society 2019.
OBJECTIVES: The introduction of liraglutide in the treatment of patients with type 2 diabetes already taking insulin is still subject to discussion in terms of timing and benefits. Gradually intensive insulin therapy is hastily prescribed. Switching from multiple insulin injection (MII) to insulin and liraglutide is evaluated in this study. METHODOLOGY: We studied 92 patients with type 2 diabetes previously under MII, C-peptide ≥ 1.5 ng/ml, divided into a group with reasonable glycemic control [RC: HbA1c < 8% (64 mmol/mol)] and another with a poor control [PC: HbA1c ≥ 8%, (64 mmol/mol)] after introduction of liraglutide and insulin therapy. RESULTS: Except for HbA1c, there were no statistical differences between RC and PC groups. Basal insulin doses were adjusted to achieve the fasting plasma glucose of 90-120 mg/dl. HbA1c was significantly improved in both groups, from 9.6% ± 1.6 (81 mmol/mol) and 7.0% ± 0.6 (53 mmol/mol) to 8.0% ± 1.5 (64 mmol/mol) and 6.8 ± 0.5% (51 mmol/mol). Reduction of body weight was significant only in RC (from 70 ± 16 kg to 68 ± 16 kg, p < 0.01). All patients from RC group and 58% of PC group reached HbA1c < 8% without hypoglycemia. CONCLUSION: This observation persuades us to propose the liraglutide and insulin combination to patients with C-peptide ≥ 1.5 ng/ml, regardless of the HbA1c. © The Japan Diabetes Society 2019.
Entities: Chemical
Keywords:
C-peptide; Diabetes; Efficacy; Liraglutide; MMI therapy; Safety
Year: 2019
PMID： 31950004 PMCID： PMC6942082 DOI： 10.1007/s13340-019-00404-x
Source DB: PubMed Journal: Diabetol Int ISSN： 2190-1678